---
title: "Clearmind Medicine Announces 1-for-10 Reverse Stock Split; Stock Down"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286961923.md"
description: "Clearmind Medicine Inc. (CMND) has announced a 1-for-10 reverse stock split effective May 21, 2026, to comply with Nasdaq's minimum bid price requirement. This will reduce its outstanding shares from 10,190,337 to approximately 1,019,033. The company's authorized share capital remains unchanged. Currently, CMND shares are trading at $0.23, down 38.02%."
datetime: "2026-05-19T20:20:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286961923.md)
  - [en](https://longbridge.com/en/news/286961923.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286961923.md)
---

# Clearmind Medicine Announces 1-for-10 Reverse Stock Split; Stock Down

(RTTNews) - Clearmind Medicine Inc. (CMND) has approved a 1-for-10 reverse stock split as part of its plan to regain compliance with Nasdaq's minimum bid price requirement, with the adjustment set to take effect on May 21, 2026.

The clinical-stage biotech company, which develops non-hallucinogenic, second-generation neuroplastogen-derived therapeutics, said the reverse split will consolidate its issued and outstanding common shares from 10,190,337 to approximately 1,019,033, subject to rounding for fractional shares. No fractional shares will be issued, and any fractional amounts will be rounded up to the nearest whole share.

The company noted that its authorized share capital will remain unchanged following the adjustment, and proportionate modifications will be made to the exercise prices and share counts of outstanding options and warrants.

Clearmind's board of directors approved the reverse split on March 18, 2026, in accordance with its articles of association. Shares will continue trading on Nasdaq under the ticker CMND.

CMND is currently trading at $0.23, down 38.02%.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

### Related Stocks

- [CMND.US](https://longbridge.com/en/quote/CMND.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABD.US](https://longbridge.com/en/quote/LABD.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)
- [GRI Bio Highlights Promising Phase 2a IPF Data, Outlook](https://longbridge.com/en/news/286422240.md)
- [David Malcom Rodman Sells 14,056 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock](https://longbridge.com/en/news/286410546.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)